2017
Natural Killer T Cells in Cancer Immunotherapy
Nair S, Dhodapkar MV. Natural Killer T Cells in Cancer Immunotherapy. Frontiers In Immunology 2017, 8: 1178. PMID: 29018445, PMCID: PMC5614937, DOI: 10.3389/fimmu.2017.01178.Peer-Reviewed Original Research
2014
Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation
Nair S, Boddupalli CS, Verma R, Liu J, Yang R, Pastores GM, Mistry PK, Dhodapkar MV. Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood 2014, 125: 1256-1271. PMID: 25499455, PMCID: PMC4335081, DOI: 10.1182/blood-2014-09-600270.Peer-Reviewed Original ResearchConceptsI NKT cellsNKT cellsB cell activationT cellsB cellsTetramer-positive T cellsType II natural killer T cellsT cell receptor usageType I NKT cellsType II NKT cellsNatural killer T cellsFollicular helper phenotypeGD mouse modelMetabolic lipid disordersKiller T cellsB cell immunityGerminal center B cellsB-cell malignanciesAntilipid antibodiesDisease activityCytokine profileChronic inflammationHelper phenotypeHumoral immunityCognate helpType II NKT-TFH Cells Against Gaucher Lipids Regulate B Cell Immunity and Inflammation
Nair S, Boddupalli C, Verma R, Liu J, Ruhua Y, Pastores G, Mistry P, Dhodapkar M. Type II NKT-TFH Cells Against Gaucher Lipids Regulate B Cell Immunity and Inflammation. Blood 2014, 124: 755. DOI: 10.1182/blood.v124.21.755.755.Peer-Reviewed Original ResearchType II NKT cellsType I NKT cellsLipid-specific T cellsI NKT cellsNKT cellsB cell immunityT cellsTFH markersAnti-lipid antibodiesΑ-GalCerGaucher diseaseB cellsCD1d tetramersTFH phenotypeCell immunityHuman PBMCsGD miceMHC-like molecule CD1dNatural killer T cellsWild-type control miceCD1d-dependent mannerDiverse NKT cellsExpansion of plasmablastsFollicular helper phenotypeAutologous B cells
2012
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, Miesowicz F, Dhodapkar KM, Dhodapkar MV. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2012, 121: 423-430. PMID: 23100308, PMCID: PMC3548165, DOI: 10.1182/blood-2012-06-435503.Peer-Reviewed Original ResearchConceptsHuman iNKT cellsINKT cellsCombination therapyAntitumor T-cell immunitySerum soluble IL2 receptorMonocyte-derived dendritic cellsNatural killer T cellsBroad immune activationLow-dose lenalidomideSoluble IL2 receptorCycles of therapyHuman NKT cellsT cell immunityKiller T cellsInnate immune cellsInduction of eosinophiliaActivation of monocytesPrevention of cancerCycles of combinationAsymptomatic myelomaClinical myelomaMeasurable diseaseClinical regressionClinical responseNKT cells